An American company tests a "slower cognitive decline" for Alzheimer's patients

The US pharmaceutical company, “Al -Lily”, announced on Wednesday that the experimental remedy for Alzheimer’s treatment “is greatly delayed as a cognitive and functional decline caused by this disease”, in results that experts describe as ‘incredible’. In a wide experience with a false treatment that has undergone about 1,200 people with early forms of Alzheimer’s, Donnimab has delayed the development of symptoms by 35% over 18 months, while measuring patients to perform daily tasks, such as running their financial affairs and practicing a car, talking about current topics. These results come to 27% in the slowdown of the development of the disease symptoms recorded by the “LikanMB” medicine, which were developed by the Japanese “Piper” and “Ezai” and the Japanese “Ezai” and the approval of the US authorities in January. ‘Ela Lily’ indicated that it would quickly increase its results for the US food and drug administration and other global regulatory bodies. “We are very pleased that the results of the clinical Donanimab were positive with a great statistics meaning for those with Alzheimer’s disease who underwent a study,” said Daniel Scroesky’s chief official and medical officials in the company. “Innocent performance” told Nick Fox of the Institute of Research to Dementia in Britain, that the results, although the complete data are not yet available, “confirm that we are at a new stage of treatments that make a change in the development of Alzheimer’s disease.” “This clinical experience is an incredible achievement as it shows a remarkable slowdown by 35% in the cognitive decline of Alzheimer’s patients who have an increase in the beta amyloid and a decrease in the tau protein.” The side effects were a time swelling in other parts of the brain at about a quarter of patients, in addition to a delicate bleeding recorded at 31% of those undergoing treatment and 14% of those who received a false medicine. Also read: